New Lanton Law Specialty Drug Blogcast with Ken Kaitin of Tufts University

biologicsBiosimilarshealthcarelife sciencespharmaceuticalspharmacyCMSFDAfintech
Written By Ron Lanton

We are excited to interview Kenneth Kaitin; Professor and Director for the Tufts Center for the Study of Drug Development at Tufts University School of Medicine in Boston, Massachusetts.

Our conversation touches on a wide variety of specialty drug issues such as oncology, orphan drugs, value based care, innovative payment models and Boston’s pharmaceutical R&D expansion.

Click here for the interview.

Ron Lanton
Previous

FCC to Vote in June on Commissioner Carr’s 5G Upgrade Order
Next

Pharmacy Times Interviews Lanton Law On How COVID-19 May Lead to the Expansion of Practice Laws for Pharmacists Across the Country